組合性保健食品配方免疫調節活性之研究

Immunomodulatory Properties of Multi-ingredient Health Food Formula

蔡明哲(Ming-Jer Tsai)

指導教授 ： 許輔

國立臺灣大學/生物資源暨農學院/園藝學研究所/碩士(2008年)

https://doi.org/10.6342/NTU.2008.10330

摘要

摘要

本研究以人蔘 (Panax ginseng)、綠茶 (Camellia sinensis)、洋甘菊 (Camellia sinensis)、五味子 (Schisandrae chinensis Baill.) 和黑加侖 (Ribes nigrum L.) 等天然植物材料之乾燥粉末，調配而得之組合性保健食品配方 A、B、C、I、K 和 J ，
以 BALB/c 小鼠分析上述配方樣品的免疫調節活性。
體內非特異性免疫調節活性結果顯示，餵食組合性保健食品配方 A 低劑量 (15.5 mg/mouse)、C 高低劑量 (15.5 mg/mouse, 3.1 mg/mouse)、I 高低劑量 (18.9 mg/mouse, 1.1 mg/mouse) 和 J 高中劑量，可顯著提高小鼠脾細胞增生率 (p<0.05)；餵食配方 A 高低劑量 (15.5 mg/mouse, 3.1 mg/mouse)、C 高劑量、I 高低劑量和 J 高中低劑量 (27.8 mg/mouse, 9.3 mg/mouse, 3.1 mg/mouse) 可顯著提升脾細胞 IFN-γ 分泌量，其中餵食 I 高劑量亦可提高 IL-2 分泌量 (p<0.05)；餵食配方 A 高低劑量、I 高劑量和 J 高中劑量可提高 NK 細胞毒殺活性 (p<0.05)；餵食配方 A 高劑量、C 低劑量、I 低劑量和 J 高中劑量可顯著提高血液中單核球細胞吞噬能力 (p<0.05)；餵食配方 A 高劑量、配方 C 高低劑量、I 高低劑量和配方 J 高中低劑量可顯著提高小鼠血清中 IFN-γ 分泌量，其中餵食 I 高低劑量和 J 高劑量亦可提高小鼠血清中 IL-2 分泌量 (p<0.05)。此外，餵食配方 A 高劑量、I 高低劑量和J 高中低劑量，可較餵食 PBS 對照組顯著提高血清中總 IgG 濃度 (p<0.05)。因此，餵食組合性保健食品配方具有調節非
特異性免疫反應之功效。
體內 OVA 特異性免疫調節活性結果顯示，餵食配方 A 高低劑量、C 高劑量、I 高低劑量和 J 高中低劑量可顯著提高小鼠 OVA 特異性脾細胞增生率(p<0.05)；餵食配方 C 高劑量、I 高劑量和 J 高中劑量可顯著提昇脾細胞 OVA 特異性IFN-γ 分泌量，其中餵食 C 高劑量和 J 高劑量亦可提高脾細胞 OVA 特異性 IL-2 分泌量 (p<0.05)，此外，餵食配方A 高低劑量、C 高低劑量、I 高低劑量和 J 高中低劑量，可較餵食 PBS 對照組顯著提高血清中 OVA 特異性
IgG 濃度 (p<0.05)。因此，餵食組合性保健食品配方具有調節 OVA 特異性免疫反應之功效。
上述結果說明餵食組合性保健食品配方 A、C、I 和J，有助於提高小鼠非特異性與 OVA 特異性免疫反應，可作為保健食品配方具備保健功效的科學
依據。

關鍵字

組合性保健食品配方 ； 非特異性免疫調節活性 ； OVA 特異性免疫調節活性

並列摘要

Abstract

The objective of this study was to evaluate the immunomodulatory effects of multi-ingredients health food formulas A, B, C, I, K and J. Results of the evaluation on non-specific immunomodulatory properties demonstrated that the administration of formula A at low dose (15.5 mg/mouse), formula C at high and low doses (15.5 and 3.1 mg/mouse, respectively), formula I at high and low doses (18.9 and 1.1 mg/mouse, respectively) and formula J at high and medium doses significantly (p<0.05) enhanced cell proliferation of mouse splenocytes. Administration of formula A at high and low doses (15.5 and 3.1 mg/mouse, respectively), formula C at high dose, formula I at high and low doses and formula J at high, medium and low doses (27.8 mg/mouse, 9.3 mg/mouse, 3.1 mg/mouse) significantly (p<0.05) increased IFN-γ secretion by mouse splenocytes. Administration of formula I at high dose significantly (p<0.05) increased IL-2 secretion by mouse splenocytes. Administration of formula A at high and low doses, formula I at high dose and formula J at high and medium doses significantly (p<0.05) enhanced the NK cell activity of mouse splenocytes. Administration of formula A at high does, formula C at low dose, formula I at low dose as well as formula J at high and medium doses significantly (p<0.05) enhanced the phagocytosis activity of monocytes. Administration of formula A at high dose, formula C at high and low doses, formula I at high and low doses and formula J at high, medium and low doses significantly (p<0.05) increased IFN-γ secretion in mouse sera. Administration of formula I at high and low doses and formula J at high dose significantly (p<0.05) increased IL-2 secretion in mouse sera. Administration of formula A at high dose, formula I at high and low doses and formula J at high, medium and low doses significantly (p<0.05) increased total IgG secretion in mouse sera. Results of the evaluation of OVA-specific immunomodulatory properties showed that administration of formula A at high and low doses, formula C at high dose, formula I at high and low doses and formula J at high, medium and low doses significantly (p<0.05) enhanced OVA-specific cell proliferation of mouse splenocytes.
Administration of formula C at high dose, formula I at high dose and formula J at high and medium doses significantly (p<0.05) increased OVA-specific IFN-γ secretion by mouse splenocytes. Administration of formula C at high and low doses, and formula J at high dose significantly (p<0.05) increased OVA-specific IL-2 secretion by mouse splenocytes. Administration of formula A at high and low doses, formula C at high and low doses, formula I at high and low doses and formula J at high, medium and low doses significantly (p<0.05) enhanced OVA-specific IgG
secretion in mouse sera. These results suggested that administration of formula A, C, I and J showed both non-specific and OVA-specific immunomodulatory activities. These data of multi-ingredient health food formulas can be used as scientific
evidences in health food applications.

Keyword : multi-ingredient health food formula, non-specific immunomodulatory
activity, OVA-specific immunomodulatory activity

並列關鍵字

multi-ingredient health food formula ； non-specific immunomodulatory activity ； OVA-specific immunomodulatory activity

參考文獻

郭肇凱。2005。七種中草藥免疫調節功能之研究。國立台灣大學園藝學研究所碩

蘇庭誼。2005。消費者購買健康食品行為之研究－以高中職學生為例。長榮大學

陳盈宜。2007。複方中草藥調節免疫及樟芝子實體抑制腫瘤之研究。國立台灣大

陳悅穎。2003。人蔘皂苷 Rh2 抗癌活性的研究。國立成功大學藥理學研究所碩

陳雅琳。2004。複方五味子芝麻萃取物對於四氯化碳誘導大白鼠。台北醫學大學